Effects of combined siRNA-TR and -TERT on telomerase activity and growth of bladder transitional cell cancer BIU-87 cells

Abstract

The effects of combined RNA interference (RNAi) of human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) genes on telomerase activity in a bladder cancer cell line (BIU-87 cells) were investigated by using gene chip technology in vitro with an attempt to evaluate the role of RNAi in the gene therapy of bladder transitional cell cancer (BTCC). Three TR-specific double-stranded small interfering RNAs (siRNAs) and three TERT-specific double-stranded siRNAs were designed to target different regions of TR and TERT mRNA. The phTR-siRNA, phTERT-siRNA, and the combination of both plasmids phTR+phTERT-siRNA were transfected into BIU-87 cells. The expression of hTR and hTERT mRNA was detected by quantitative fluorescent reverse transcription-polymerase chain reaction, and a telomeric repeat amplification protocol was applied to detect telomerase activity. Growth inhibition of BIU-87 cells was measured by MTT assay. Gene chip analysis was performed to evaluate the effects of the combined RNAi of hTR+hTERT genes on telomerase activity and growth of BIU-87 cells in vitro. The results showed that the expression of hTERT and hTR mRNA was inhibited by pRNAT-hTERT-III, pRNAT-hTR-III, and pRNAT-hTR-III+hTERT-III in BIU-87 cells. The inhibition efficiency of pRNAT-hTERT-III, pRNAT-hTR-III, pRNAT-hTERT-III+pRNAT-hTR-III was 67% for TERT mRNA, 41% for TR mRNA, 57% for TR mRNA and 70% for TERT mRNA in BIU-87 cells respectively. The growth of BIU-87 cells was inhibited and telomerase activity was considerably decreased, especially in the cells treated with combined RNAi-hTR and -hTERT. Gene chip analysis revealed that 21 genes were down-regulated (ATM, BAX, BCL2, BCL2L1, BIRC5, CD44, CTNNB1, E2F1, JUN, MCAM, MTA1, MYC, NFKB1, NFKBIA, NME4, PNN, PNN, SERPINE1, THBS1, TNFRSF1A, and UCC1). The results indicated that hTR-siRNA and hTERT-siRNA, especially their combination, siRNA hTR+hTERT, specifically and effectively suppressed the expression of both hTR and hTERT mRNA and telomerase activity. Molecular biological mechanism by which combined siRNA-TR and -TERT inhibited telomerase activity and growth of BIU-87 cells in vitro may involve the down-regulation of the 21 genes.

Keywords

human telomerase reverse transcriptase / combined RNAi / hTR gene / hTERT gene / transitional cell bladder cancer

References

[1] NakatsukasaH., OnishiT., KaneyoshiT., et al.. Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer, 2000, 82(4): 833-837

[2] LordR.V., SalongaD., DanenbergK.D., et al.. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg, 2000, 4(2): 135-142

[3] KonagiY., KabayashiD., YajimaT., et al.. Telomerase activity is down regulated via decreases in hTERT but not TEP1 mRNA or hTERC during the differentiation of leukemic cells. Anticancer Res, 2000, 20(2A): 773-778

[4] WatanabeN.. . Telomerase, cell immortality and cancer Hokkaido Igaku Zasshi, 2001, 76(3): 127-132

[5] RhyaM.S.. Telomeres telomerase and immortality. J Natl Cancer Ins, 1995, 87(12): 884-894

[6] ZouL., ZhangP., LuoC., et al.. shRNA targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol, 2006, 57(3): 328-334

[7] ItoH., KyoS., KanayaT., et al.. Expression of human telomerase subunit and correlation with telomerase activity in urothelial cancer. Clin Cancer Res, 1998, 4(7): 1603-1608

[8] LancelinF., AnidjarM., VilletteJ.M., et al.. Telomerase activity as a potential marker in preneoplastic bladder lesions. BJU Int, 2000, 85(4): 526-531

[9] SuzukiT., SuzukiY., FujiokaT.. Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer. J Urol, 1999, 162(6): 2217-2220

[10] GlasgowJ.N., EvertsM., CurielD.T.. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther, 2006, 13(9): 830-844

[11] ElbashirS.M., LendeckelW., TuschlT.. RNA interference is mediated by 21- and 22- nucleotide RNAs. Gene Dev, 2001, 15(2): 188-200

[12] OeggerliM., TomovskaS., SchramlP., et al.. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene, 2004, 23(33): 5616-5623

[13] WuX., DengY., WangG., TaoK.. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J Surg Res, 2007, 183(1): 56-63

[14] LinY., UemuraH., FujinamiK., et al.. Telomerase activity in primary prostate cancer. J Urol, 1997, 157(3): 1161-1165

[15] WuK.J., GrandoriC., AmackerM., et al.. Direct activation of Tert transcription by c-myc. Nature Genet, 1999, 21: 220-224^(2

[16] SuenagaM., YamaguchiA., SodaH., et al.. Antiproliferative effects of Gefitinib are associated with suppression of E2F1 expression and telomerase activity. Anticancer research, 2006, 26(5A): 3387-3392

[17] PirocanacE.C., NassirpourR., YangM., et al.. Bax-induction gene therapy of pancreatic cancer. J Surg Res, 2002, 106(2): 346-351

[18] MalerbaI., GribaldoL., DiodovichC. I.. nduction of apoptosis and inhibition of telomerase activity in human bone marrow and HL-60 p53 null cells treated with anti-cancer drugs. Toxicology in Vitro, 2005, 19(4): 523-532

[19] AngèleS., FalconerA., et al.. ATM protein overexpression in prostate tumors. Anatomic Pathology, 2004, 121(2): 231-236

[20] FeldserD., StrongM. A., GreiderC. W., et al.. Ataxia telangiectasia mutated (Atm) is not required for telomerase-mediated elongation of short telomerase. Cancer Res, 2003, 63: 8188-8196

[21] ShilohY.. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer, 2003, 3(3): 155-168

[22] MetcalfeJ.A., ParkhillJ., CampbellL., et al.. Accelerated telomere shortening in ataxia telangiectasia. Nat-Genet, 1996, 13(3): 350-353

[23] GreenwellP.W., KronmoalS.L., PorterS.E., et al.. TEL1, a gene involved in controlling telomere length in S. cerevisiae, is homologous to the human ataxia telangiectasia gene. Cell, 1995, 82(5): 823-829

[24] DuBoisM.L., HaimbergerZ.W., MclntoshM.W., et al.. A quantitative assay for telomere protection in Saccharomyces cerevisiae. Genetics, 2002, 161(3): 995-1013

[25] FujimotoK., TakahashiM.. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against C-myc mRNA. Biochem Biophys Res Commun, 2007, 24(3): 775-781

[26] LatilA., VidaudD., ValeriA., et al.. hTERT expression correlates with Myc over-expression in human prostate cancer. Int J Cancer, 2000, 89(2): 172-1797